Table 3.

Risk of Epilepsy in Statin Users and Nonusers.

	Statin User
Variable	No (%)	Yes (%)	OR	95% CI	P Value
Primary analyses
PS-matched general cohort: 6342 nonusers and 6342 statin users	141 (2.2)	114 (1.8)	0.91a 0.91b 0.81c	0.67–1.23 0.67–1.22 0.63–1.03	0.54 0.52 0.09
PS-matched healthy cohort: 3351 nonusers and 3351 statin users	46 (1.4)	37 (1.1)	1.08a 1.08b 0.80c	0.64–1.83 0.64–1.82 0.52–1.24	0.76 0.78 0.32
Secondary analyses
General cohort: 29 812 nonusers and 13 626 statin users	443 (1.5)	327 (2.4)	0.97a	0.75–1.25	0.78
Healthy cohort: 21 987 nonusers and 3982 statin users	246 (1.1)	43 (1.1)	0.94a	0.60–1.48	0.80
Epilepsy-incident general cohort: 29 602 nonusers and 13 517 statin users	261 (0.9)	240 (1.8)	0.99d	0.76–1.29	0.95
Epilepsy-incident healthy cohort: 21 885 nonusers and 3917 statin users	150 (0.7)	33 (0.8)	0.88d	0.61–1.52	0.97

Abbreviations: OR, odds ratio; PS, propensity score.

^aAdjusted OR: adjusting for epilepsy at baseline and propensity score.

^bAdjusted odds ratio: adjusting for epilepsy at baseline.

^cUnadjusted odds ratio using conditional logistic regression analysis.

^dAdjusted OR: adjusting for propensity score.